Broad-spectrum activity of a novel antibiotic peptide against multidrug-resistant veterinary isolates

Vet J. 2013 Nov;198(2):534-7. doi: 10.1016/j.tvjl.2013.08.020. Epub 2013 Aug 27.

Abstract

The emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) bacteria has become a medical and veterinary problem. Antimicrobial peptides (AMPs) show potential to overcome antibiotic resistance and could be used therapeutically. A novel AMP (AMP2041) was developed in silico and its microbiocidal activity against MDR clinical strains isolated from cattle (n=6), dogs (n=8), and pigs (n=20) was evaluated. AMP2041 showed strong antimicrobial activity against all Gram-positive and Gram-negative MDR clinical strains tested. Within 20 min of incubation, there was complete killing of Pseudomonas aeruginosa ATCC 27953 and a 90% reduction of colony count for Escherichia coli ATCC 25922. For Staphylococcus aureus ATCC 25923, a 90% reduction of colony count was observed within 120 min of incubation.

Keywords: Antibiotic peptides; Antimicrobial resistance; MDR bacteria; Veterinary isolates.

MeSH terms

  • Animals
  • Antimicrobial Cationic Peptides / pharmacology*
  • Cattle
  • Cattle Diseases / drug therapy*
  • Cattle Diseases / microbiology
  • Dog Diseases / drug therapy*
  • Dog Diseases / microbiology
  • Dogs
  • Drug Resistance, Multiple, Bacterial*
  • Gram-Negative Bacteria / drug effects*
  • Gram-Positive Bacteria / drug effects*
  • Swine
  • Swine Diseases / drug therapy*
  • Swine Diseases / microbiology

Substances

  • AMP2041
  • Antimicrobial Cationic Peptides